clinical trial · NCT05553834
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
Non-small Cell Lung Cancer (NSCLC)Alirocumab and Cemiplimab
brief summary
PCSK9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface MHC class 1 molecules. This study will evaluate if combining the anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab can generate anti-tumor activity and clinical responses in patients with metastatic lung cancer who have progressed on first line immune checkpoint blockade therapy.
started
May 16, 2023
primary completion
Sep 16, 2025
completion
Nov 1, 2026
last updated
Apr 13, 2026
official title
A Phase II Study of PCSK9 Inhibitor Alirocumab and PD-1 Inhibitor Cemiplimab in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung Cancer: TOP2201
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol